C4 Therapeutics reports FY2024 revenue $35.6M, net loss $1.52/sh; cash runway into 2027

C4 Therapeutics, Inc.

2024-FY EPS reported -$1.52 revenue$35,584,000

FY2024 revenue $35.6M (vs $20.8M in FY2023); net loss $105.3M ($1.52/sh) vs $132.5M ($2.67).
Cash $267.3M at Dec 31, 2024; expected to fund operations into 2027.
Cemsidomide dose escalation continues; next-phase trials expected to start in early 2026.
CFT1946 Phase 1/2 progressing; data in melanoma and CRC expected H2 2025.
Appointed Steve Hoerter to board; initiated CFT8919 Phase 1 in Greater China with Betta.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.